Market Cap 111.38B
Revenue (ttm) 48.30B
Net Income (ttm) -8.95B
EPS (ttm) N/A
PE Ratio 8.27
Forward PE 8.31
Profit Margin -18.53%
Debt to Equity Ratio 2.63
Volume 8,140,414
Avg Vol 16,360,900
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 95%
Beta 0.29
Analysts Sell
Price Target $54.67

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
3DBuilds
3DBuilds Dec. 26 at 10:35 PM
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 26 at 8:49 PM
$SLS Massive ROI INCOMING Here - Not Potential ROI - GUARANTEED ROI. - ALL SINCE THE IDMC UNBLINDED ACTUAL PHASE 3 Trial RESULTS - ACTUAL MOS and IR Data from the Interim Analysis THAT TELL ALL OF US WHO UNDERSTAND THE AML Market - including $ABBV / $BMY / $RHHBY - that GPS is absolutely 100% for SURE Getting FDA APPROVAL. - SLS share price is up 300% - SLS Market Cap is up 450% - SLS Institutional Investors up to 154, from Just 39 - SLS Cash on Hand up to $74M from just 13M - SLS Call to Put Ratio 99.91 to 0.09 JUST BECAUSE YOU MAY NOT UNDERSTAND OR HAVE ALL THE FACTS - SMART MONEY DOES.
1 · Reply
Chartist0_0
Chartist0_0 Dec. 26 at 4:59 PM
$BMY added a 1000s at 54.51$. See 63 plus in March plus a good dividend payment.
1 · Reply
Chartist0_0
Chartist0_0 Dec. 26 at 4:18 PM
$BMY watching for a late day collapse in this name. Just technical, no news.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 26 at 1:18 AM
Comparing trending tickers $BMY vs $PPLT: BMY is slightly up by 0.79% at $54.71, with its trading volume at 10.0M shares, below its average of 14.0M. In contrast, PPLT has dipped by 1.69% to $204.52, but sees a significant surge in trading volume at 3.5M shares, nearly 10x its average volume of 368.0K. While BMY shows a modest increase on a lighter trading day, PPLT's price has declined despite a substantial increase in trading activity.
0 · Reply
1iquid
1iquid Dec. 26 at 12:51 AM
💎 Liquid® Live Actionable Trade Asset: $BMY Contracts: $BMY January 15, 2027 $55 Calls Scale in: $5.13- $6.27 Scale out: $19.95-$34.20 Profit Potential : 145% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 12:40 AM
🔎 $BMY Options Scan Update (18:40 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 25 at 6:21 PM
Enter: $BMY Calls Strike Price: $55 Expiry Date: JAN 16 2026 Buy in Price: $0.82 - $0.85 Sell Price: $1.43 Profit : +75% (Turn every $1 into $1.75) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
W15E
W15E Dec. 25 at 4:37 PM
$BMY keeping close tabs on this one
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:29 PM
$BMY Actionable Trade Alert: Market Context: $BMY closed at $54.71, near its 60D high of $54.86, indicating bullish momentum. The RSI at 66.31 suggests the stock is approaching overbought territory, but not excessively so, allowing for further upside potential. Directional Bias: The stock shows a strong upward trend, supported by the MA30 at $50.48 and MA50 at $48.26, both below the current price. The proximity to the 60D high indicates potential resistance, but the overall trend remains positive. Trade Plan: - Suggested Entry: $54.75 (slightly above the last close) - Stop Loss: $52.50 (approximately 4.0% below entry) - Take Profit Targets: 1. $56.00 (Target 1: 2.3% ROI) 2. $57.50 (Target 2: 5.1% ROI) 3. $64.00 (Target 3: 16.9% ROI) This plan provides a solid risk-reward ratio, with the potential for a 17%+ ROI on the final target. Monitor the trade closely as it approaches key levels. https://privateprofiteers.com
1 · Reply
Latest News on BMY
Jenny Harrington's top dividend plays for 2026

Dec 23, 2025, 1:56 PM EST - 3 days ago

Jenny Harrington's top dividend plays for 2026

AMCR ENB VICI


3 Top Value Stocks to Buy and Hold for 2026

Dec 23, 2025, 11:00 AM EST - 3 days ago

3 Top Value Stocks to Buy and Hold for 2026

CPB STZ


Final Trade: NCNO, LION, SNAP, BMY

Dec 22, 2025, 6:18 PM EST - 4 days ago

Final Trade: NCNO, LION, SNAP, BMY

NCNO LION SNAP


Final Trade: JNJ, NVO, UBER, BMY

Dec 15, 2025, 6:22 PM EST - 10 days ago

Final Trade: JNJ, NVO, UBER, BMY

JNJ NVO UBER


Bristol Myers Squibb Announces Dividend Increase

Dec 10, 2025, 4:16 PM EST - 16 days ago

Bristol Myers Squibb Announces Dividend Increase


What Is Happening With BMY Stock?

Dec 1, 2025, 9:50 AM EST - 25 days ago

What Is Happening With BMY Stock?


Bristol Myers Squibb to Host Hematology-Focused Investor Event

Nov 24, 2025, 6:59 AM EST - 4 weeks ago

Bristol Myers Squibb to Host Hematology-Focused Investor Event


Bristol Myers, Sanofi sued by Texas over Plavix

Nov 20, 2025, 4:06 PM EST - 5 weeks ago

Bristol Myers, Sanofi sued by Texas over Plavix

SNY


This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.

Nov 20, 2025, 8:00 AM EST - 5 weeks ago

This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.


Why Bristol-Myers Squibb Remains Undervalued In 2025

Nov 18, 2025, 9:26 AM EST - 5 weeks ago

Why Bristol-Myers Squibb Remains Undervalued In 2025


3DBuilds
3DBuilds Dec. 26 at 10:35 PM
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 26 at 8:49 PM
$SLS Massive ROI INCOMING Here - Not Potential ROI - GUARANTEED ROI. - ALL SINCE THE IDMC UNBLINDED ACTUAL PHASE 3 Trial RESULTS - ACTUAL MOS and IR Data from the Interim Analysis THAT TELL ALL OF US WHO UNDERSTAND THE AML Market - including $ABBV / $BMY / $RHHBY - that GPS is absolutely 100% for SURE Getting FDA APPROVAL. - SLS share price is up 300% - SLS Market Cap is up 450% - SLS Institutional Investors up to 154, from Just 39 - SLS Cash on Hand up to $74M from just 13M - SLS Call to Put Ratio 99.91 to 0.09 JUST BECAUSE YOU MAY NOT UNDERSTAND OR HAVE ALL THE FACTS - SMART MONEY DOES.
1 · Reply
Chartist0_0
Chartist0_0 Dec. 26 at 4:59 PM
$BMY added a 1000s at 54.51$. See 63 plus in March plus a good dividend payment.
1 · Reply
Chartist0_0
Chartist0_0 Dec. 26 at 4:18 PM
$BMY watching for a late day collapse in this name. Just technical, no news.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 26 at 1:18 AM
Comparing trending tickers $BMY vs $PPLT: BMY is slightly up by 0.79% at $54.71, with its trading volume at 10.0M shares, below its average of 14.0M. In contrast, PPLT has dipped by 1.69% to $204.52, but sees a significant surge in trading volume at 3.5M shares, nearly 10x its average volume of 368.0K. While BMY shows a modest increase on a lighter trading day, PPLT's price has declined despite a substantial increase in trading activity.
0 · Reply
1iquid
1iquid Dec. 26 at 12:51 AM
💎 Liquid® Live Actionable Trade Asset: $BMY Contracts: $BMY January 15, 2027 $55 Calls Scale in: $5.13- $6.27 Scale out: $19.95-$34.20 Profit Potential : 145% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 12:40 AM
🔎 $BMY Options Scan Update (18:40 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 25 at 6:21 PM
Enter: $BMY Calls Strike Price: $55 Expiry Date: JAN 16 2026 Buy in Price: $0.82 - $0.85 Sell Price: $1.43 Profit : +75% (Turn every $1 into $1.75) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
W15E
W15E Dec. 25 at 4:37 PM
$BMY keeping close tabs on this one
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:29 PM
$BMY Actionable Trade Alert: Market Context: $BMY closed at $54.71, near its 60D high of $54.86, indicating bullish momentum. The RSI at 66.31 suggests the stock is approaching overbought territory, but not excessively so, allowing for further upside potential. Directional Bias: The stock shows a strong upward trend, supported by the MA30 at $50.48 and MA50 at $48.26, both below the current price. The proximity to the 60D high indicates potential resistance, but the overall trend remains positive. Trade Plan: - Suggested Entry: $54.75 (slightly above the last close) - Stop Loss: $52.50 (approximately 4.0% below entry) - Take Profit Targets: 1. $56.00 (Target 1: 2.3% ROI) 2. $57.50 (Target 2: 5.1% ROI) 3. $64.00 (Target 3: 16.9% ROI) This plan provides a solid risk-reward ratio, with the potential for a 17%+ ROI on the final target. Monitor the trade closely as it approaches key levels. https://privateprofiteers.com
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 12:10 AM
$BMY Current Stock Price: $54.65 Contracts to trade: $55 BMY Dec 26 2025 Call Entry: $0.09 Exit: $0.13 ROI: 39% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
stu4
stu4 Dec. 24 at 6:54 PM
$AGIO suggest you go back to 2018 !! when it was $48, the Fouse stepped on the property , and unlike Yvonne Greenstreet at $ALNY ….FOUSE CUT THE STOCK IN HALF IN 7 YEARS , Follow on GOFF, after 3 years produced negative 17 CENTS in 3 years Remember, you nim rod, FOUSE and Schenkien gave $BMY , $48.75 for their shares ….HOW ARE YOU FAIRING , as compared to Bristol Myers , you buffoon ! @Mindmld Suggest , taking the foot out of your dumb mouth
1 · Reply
Reanimated666
Reanimated666 Dec. 24 at 5:26 PM
$BMY Bristollll Myyyyyers
0 · Reply
Carmenfean
Carmenfean Dec. 24 at 5:04 PM
0 · Reply
RhoRisk
RhoRisk Dec. 24 at 4:05 PM
$BMY Sustained appreciation requires execution consistency across macro cycles and demand regimes, with outcomes shaped by timing and discipline. Uncertainty remains until results confirm narrative.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 24 at 4:00 PM
$SLS 2nd Day in a Row, Cracked the 52 week High -- you see what's happening - and it is exactly what you would like to see ahead of the Phase 3 Results. - the Share Price will Continue Climbing Until it absolutely Launches PSA: Industry Players $ABBV $BMY $RHHBY KNOW precisely how their Drugs - AzaVEN - Best Available Treatment BAT perform for the SLS Phase 3 Control Arm Patients - 2 AzaVEN Phase 3 Trials Have recently FAILED - AML Maintenance Trials VIALE-M - AML First Remission Maintenance Trial TERMINATED due to Toxicity VIALE-T - AML Post Transplant Maintenance Trial Terminated due to Toxicity. --- and SLS Mcap is Now Up 500% Since the IDMC Unblinded the INTERIM ALL Pooled Phase 3 MOS and IR DATA. Institutional Funds are up to 154 last report (its more now), up from just 39, when the IDMC Unblinded ActualPhase 3 MOS DATA. Call to Put ratio is 99.99 to 0.01 SLS had 13M in Cash its Now $74M Runway into 2028.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 8:32 AM
Enter: $BMY Calls Strike Price: $55 Expiry Date: JAN 16 2026 Buy in Price: $0.93 - $0.98 Sell Price: $2.12 Profit : +128% (Turn every $1 into $2.28) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 7:49 PM
Is $BMY a hidden gem at a discount? 📉💎 Bristol Myers Squibb's shares are down 5.3% over the past year, trading at a forward P/E of 9.07x — below the large-cap pharma industry’s 17.27x. With Eliquis, its top revenue generator, seeing an 8% sales increase in the first nine months of 2025, how will the new pricing deal impact future performance? Opportunity assessment here 👉 https://www.zacks.com/stock/news/2808195/will-the-recent-pricing-deal-with-the-government-impact-bmys-sales?cid=sm-stocktwits-2-2808195-body-26104&ADID=SYND_STOCKTWITS_TWEET_2_2808195_BODY_26104
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 6:49 PM
Free drug deal with the government — is this a sales headwind for $BMY? ⚠️ Bristol Myers Squibb agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis, raising real questions about future sales impact. Find out what this means for BMY’s revenue outlook 👉 https://www.zacks.com/stock/news/2808195/will-the-recent-pricing-deal-with-the-government-impact-bmys-sales?cid=sm-stocktwits-2-2808195-teaser-26103&ADID=SYND_STOCKTWITS_TWEET_2_2808195_TEASER_26103
0 · Reply
parcha
parcha Dec. 23 at 6:37 PM
https://youtube.com/watch?v=RqmqJIJ4nLg&si=eY5lKXUCiZNpB6S3 $BMY Bristol-Myers Squibb (BMY): (1:20) The company has a strong drug portfolio and pipeline, supporting its wide economic moat (1:25-1:33). While facing a significant patent cliff for 47% of its revenue through 2028, newer therapies, promising pipeline programs, and cost-cutting efforts are expected to mitigate the impact (1:35-1:56). Morningstar believes the market underestimates Bristol's ability to weather this challenge and values the stock at $66 per share, considering it significantly undervalued (1:56-2:03).
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 23 at 5:22 PM
$BMY Speaking of Peptides $SLS the GPS Galinpepimut-S Immunotherapy for AML Remission Maintenance Phase 3 Trial Results are Imminent - Expected ANY DAY NOW and worth 80X the Current Mcap ... Phase 3 Results - 5 years in the Making - Expected BY YEAR End. Considering the positive P3 Result will give GPs the Green light to treat upwards of 25,000 AML Remission Patients each year and 100,000 Right Now Currently in Remission who'll benefit - The Short manipulated SLS share price will continue to climb until we see the Results and then the share Price Launches.
0 · Reply
biolover
biolover Dec. 23 at 3:59 PM
$VKTX well they are different peptides. So u can’t do mg for mg But like the sc dual agonists are better tolerated and more effective than single GLP1 like $NVO sema , the oral dual agonist will be more effective and better tolerated. Viking needed to make pills smaller and they worked on that per CEO. Novo CEO should partner with Viking ( not for sale ) and he can easily catch up to $LLY in 2-3 years.. there is oral amylin coming from Viking as well Amgen , Roche and Pfizer don’t have competitive drugs. If $ABBV or $BMY gets to Viking drugs first , good luck to Doustdar
0 · Reply